Organogenesis Holdings Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Gary S. Gillheeney
- Full Time Employees
- 854
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 85 Dan Road Canton MA United States of America 02021
- IPO Date
- Jan 5, 2017
- CIK
- 0001661181
- Website
- organogenesis.com
- Similar Companies
- Business
- Organogenesis Holdings Inc. (Nasdaq: ORGO) is a leading regenerative medicine company that develops, manufactures, and commercializes bioactive and acellular biomaterial solutions for advanced wound care, surgical, and sports medicine markets primarily in the United States. Founded in 1985 as a spin-off from regenerative technology developed at the Massachusetts Institute of Technology, the company maintains headquarters in Canton, Massachusetts, with additional facilities in Birmingham, Alabama; Norwood and Canton, Massachusetts; St. Petersburg, Florida; and an Innovation Center in San Diego, California. Its advanced wound care portfolio includes Apligraf, a bioengineered living cell therapy for venous leg ulcers and diabetic foot ulcers; Dermagraft, a bioengineered product producing human collagen, extracellular matrix proteins, and cytokines for chronic diabetic foot ulcers; PuraPly antimicrobial matrices such as PuraPly AM, PuraPly XT, PuraPly MZ, and PuraPly SX featuring native extracellular matrix scaffolds combined with broad-spectrum PHMB antimicrobial barrier; placental allografts including Affinity and Novachor preserving viable cells, growth factors, cytokines, and intact extracellular matrix; NuShield, a multi-layered dehydrated amnion/chorion membrane allograft; CYGNUS Dual and CYGNUS Matrix, complete dehydrated placental allografts retaining all native tissue layers; VIA Matrix, a multi-layer placental membrane; and SimpliGraft, a thin, flexible amnion-only allograft; while surgical and sports medicine offerings encompass FortiShield biosynthetic wound matrix, FiberOS and OCMP bone void fillers for orthopedic and neurosurgical applications, and PuraForce bioengineered porcine collagen surgical matrix. Recent developments include the November 2024 closing of a $130 million Series A Convertible Preferred Stock investment from Avista Healthcare Partners to support growth initiatives; a November 2024 stock repurchase agreement with GN 2016 Family Trust; ongoing progress in the ReNu clinical program and RENEW trial for potential new offerings; and strategic focus on reimbursement expansions, salesforce growth, and market penetration amid positive Q3 2024 revenue performance exceeding expectations.
Organogenesis Q2 Earnings Call Highlights
Organogenesis Holdings Inc. (ORGO) Q2 2026 Earnings Call Transcript
Organogenesis Holdings Inc. Reports Second Quarter 2026 Financial Results
Organogenesis Announces Publication of Peer-Reviewed Clinical Trial Results Demonstrating Clinical Benefit of Affinity™ in the Most Challenging and Complex Venous Leg Ulcers
Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2026 Financial Results on August 6, 2026
Organogenesis Announces FDA Acceptance of Biologics License Application for ReNu® for the Management of Symptomatic Knee Osteoarthritis
Organogenesis: Mesmerized By Wound Care Struggles, Upcoming ReNu Blockbuster Overlooked
Organogenesis Q1 Earnings Call Highlights
Organogenesis Holdings Inc. (ORGO) Q1 2026 Earnings Call Transcript
Organogenesis Holdings Inc. Reports First Quarter 2026 Financial Results
Organogenesis Completes Rolling Submission of Biologics License Application for ReNu®
What's Going On With Organogenesis Stock On Wednesday?
Organogenesis: Clinical Win De-Risks 2026, Recovery In Sight
Organogenesis Stock Rockets After Diabetic Foot Ulcer Trial Posts Statistically Significant Win
Organogenesis Achieves Primary Endpoint in Randomized Controlled Trial of PuraPly®AM
Organogenesis Announces Successful FDA Meeting and Plan to File BLA for ReNu® for Knee Osteoarthritis Pain
Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2026 Financial Results on May 7, 2026
SG Americas Securities LLC Acquires 376,623 Shares of Organogenesis $ORGO
Organogenesis Holdings Inc. (ORGO) Q4 2025 Earnings Call Transcript
Organogenesis Holdings Inc. Reports Fourth Quarter 2025 Financial Results, Posts Record Revenue